Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
This study is investigating a new medication called AGMB-129, designed for a specific type of Crohn's disease called fibrostenotic Crohn's. This trial is an early-stage study involving healthy volunteers, not people with Crohn's disease. The main goal is to understand how the body absorbs this new medicine and whether eating food around the time of taking it changes how much medicine gets into the bloodstream. This information is really important because it helps scientists work out the best way to give the medicine in future studies. By carefully testing the medicine in healthy people first, they learn valuable information about its properties before giving it to patients who are unwell. This helps ensure future trials are as safe and effective as possible.
At a glance
What is this study about?
This study is a very early stage of testing for a new medicine called AGMB-129, which is being developed for a specific form of Crohn's disease called fibrostenotic Crohn's. "Fibrostenotic" means that the disease has caused scarring (fibrosis) and narrowing (stenosis) in the bowel, which can lead to blockages and other serious problems. Before this new medicine can be tested in people who have Crohn's disease, researchers need to understand how it behaves in the human body.
The main purpose of this study is to look at something called "relative bioavailability." This just means they want to see how much of the medicine gets into your bloodstream and how quickly. They also want to find out if eating food at the same time as taking the medicine changes how it's absorbed. For example, some medicines are absorbed better on an empty stomach, while others need to be taken with food. Understanding this helps doctors know the best way to tell future patients to take the medicine.
Because this is such an early study, it actually involves healthy people, not those with Crohn's disease. This approach allows researchers to focus purely on how the body handles the medicine without the complexities of an illness. This type of study is a crucial first step in developing any new medication, helping to gather important safety and dosing information before moving on to studies with patients.
Key takeaways
- This is an early-stage study for a new Crohn's disease medicine.
- It aims to understand how the body absorbs the medicine and if food affects it.
- Only healthy adult volunteers are taking part, not patients with Crohn's.
- It helps gather important information before the medicine can be tested in patients.
- Taking part means multiple clinic visits and blood tests.
- You would contribute to future medical advancements.
Who may be eligible?
To be able to take part in this study, you need to be at least 18 years old. There isn't an upper age limit, meaning people of all adult ages can be considered. The study is open to both men and women.
Since this is a study looking at how a new medicine behaves in a healthy body, you would need to be generally in good health. This means you wouldn't have any serious ongoing medical conditions, particularly those that might affect how your body absorbs, processes, or gets rid of medicines. The research team would carry out a thorough health check to make sure you are suitable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Do you have no serious ongoing medical conditions?
- Are you comfortable with attending multiple clinic visits?
- Are you comfortable with having regular blood samples taken?
What does participation involve?
If you decide to take part in this study, you would likely have an initial screening visit where doctors would check your general health, possibly take blood and urine samples, and review your medical history to make sure you meet all the study requirements.
After that, you would typically attend several study visits for the actual testing. This might involve staying overnight in a clinic or visiting frequently over a short period. During these visits, you would be given the study medicine, AGMB-129, and the researchers would regularly take blood samples to measure how much of the medicine is in your system. They would also monitor your health closely, checking things like your blood pressure, heart rate, and temperature. You might be asked to take the medicine on an empty stomach during one visit, and with a meal during another, to see the effect of food.
The total duration of your involvement could range from a few days to a few weeks, depending on the specific schedule of the study visits and follow-up checks. There will be at least one follow-up visit or call after you've finished taking the medication to ensure you are well.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is fibrostenotic Crohn's disease?
It's a type of Crohn's disease where scarring and narrowing occur in the bowel, which can cause blockages and other problems.
Why is this study in healthy people, not people with Crohn's?
This early study helps researchers understand how the new medicine works in the body and if food affects it, without the complications of an existing illness.
Will I get the actual medicine if I have Crohn's disease?
No, this study is for healthy volunteers only. The medicine is not yet available for people with Crohn's disease.
What does 'relative bioavailability' mean?
It refers to how much of the medicine gets into your bloodstream and how quickly, which helps determine the best way to take it.
Will I be paid for taking part?
Studies often offer some payment for your time and inconvenience, but this would be discussed fully during the consent process.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.